At the time of writing, Autolus Therapeutics plc ADR [AUTL] stock is trading at $4.14, up 0.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AUTL shares have gain 4.02% over the last week, with a monthly amount glided 4.81%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 09, 2023, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $10. On March 17, 2023, Bryan Garnier initiated with a Buy rating and assigned a price target of $5 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $12 on June 14, 2021. JP Morgan downgraded its rating to a Neutral but $9 remained the price target by the analyst firm on January 29, 2021. In a note dated July 31, 2020, JP Morgan initiated an Overweight rating.
For the past year, the stock price of Autolus Therapeutics plc ADR fluctuated between $2.21 and $7.45. Currently, Wall Street analysts expect the stock to reach $9.5 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $4.14 at the most recent close of the market. An investor can expect a potential return of 129.47% based on the average AUTL price forecast.
Analyzing the AUTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -15.19%, Pretax Profit Margin comes in at -18.46%, and Net Profit Margin reading is -19.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.67 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.99 points at the first support level, and at 3.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.34, and for the 2nd resistance point, it is at 4.53.
Ratios To Look Out For
It is important to note that Autolus Therapeutics plc ADR [NASDAQ:AUTL] has a current ratio of 18.50. Also, the Quick Ratio is 18.50, while the Cash Ratio stands at 17.28. Considering the valuation of this stock, the price to sales ratio is 104.90, the price to book ratio is 2.09.
Transactions by insiders
Recent insider trading involved Martin Pule, Officer, that happened on Sep 16 ’24 when 0.7 million shares were purchased.
